We recently demonstrated that treatment of diabetic nephropathy patients with the sodium-glucose cotransporter inhibitor (SGLT2i) dapaglifozin led to small but significant increases in serum phosphate, plasma PTH, and FGF23, independent of concomitant changes in eGFR or 24-h albumin excretion [83••]. The gene discussed is PTH; the disease is diabetic kidney disease.